Clinical Trials

Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication

Pluristem Therapeutics Inc , a leading developer of placenta-based cell therapy products, today announced that it has completed enrollment of all 172 patients in a multinational Phase II trial of its PLX-PAD cells in the treatment of intermittent claudication (IC), a peripheral...

Visterra doses first patient in phase IIa trial for VIS410 for Influenza A

Visterra, Inc , a clinical-stage biopharmaceutical company announced that the first patient was dosed in a Phase 2a clinical trial of VIS410, a monoclonal antibody in development for the treatment of hospitalized patients with influenza A, regardless of the viral strain....

Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118

Valeant Pharmaceuticals International, Inc. announced positive results from a second confirmatory pivotal Phase 3, multicenter double-blind, randomized, vehicle-controlled clinical study to assess the safety and efficacy of IDP-118 (halobetasol propionate and tazarotene) lotion in the treatment of plaque psoriasis....

Clinerion enters South America, as Brazil’s iHealth Group joins the Patient Recruitment System platform

The iHealth Group of Brazil joins the Patient Recruitment System platform as Clinerion's first hospital cluster in South America. iHealth brings PRS a potential access to 40 sites and a 25 M patient population, opening up...

Renova Therapeutics selects Worldwide Clinical Trials as its CRO for RT-100 AC6 gene transfer

Renova  Therapeutics, a biotechnology company developing gene therapy treatments for congestive heart failure and type 2 diabetes.  Announced that it has selected Worldwide Clinical Trials as its CRO for a Phase 3 study of RT-100 AC6...

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera for Treatment of Dry Eye 

Sun Pharma (SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies), announced successful Phase 3 confirmatory clinical trial results for Seciera™ (cyclosporine A, 0.09% ophthalmic solution). For the treatment...

Protalix BioTherapeutics Announces Positive results from Phase II Clinical Trial of alidornase alfa

Protalix BioTherapeutics Inc announced positive interim results from the Company’s phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis (CF) for the first 13 CF patients enrolled in the study.   Fifteen...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »